Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;74(1):63-8.
doi: 10.4103/0250-474X.102545.

Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital

Mylapuram Rama  1 , Gayathri Viswanathan, Leelavathi D Acharya, R P Attur, P N Reddy, S V Raghavan
Affiliations

Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital

Mylapuram Rama et al. Indian J Pharm Sci. 2012 Jan.

Abstract

Polypharmacy is common in drug prescriptions of chronic kidney disease patients. A study of the prescription patterns of drugs with potential interactions would be of interest to prevent drug related adverse events. A prospective observational study of six months (Dec 2009-May 2010) was carried out among the chronic kidney disease patients admitted to the nephrology ward of a South Indian tertiary care hospital. The pattern and rates of drug-drug interactions seen in the prescriptions of these patients was studied. Among the 205 prescriptions included, a total of 474 interactions were reported, making 2.7 interactions per prescription with incidence rates of 76.09%. Around 19.62% of interactions were of major severity. Most common interactions were found between ascorbic acid and cyanocobalamine (12.45%), clonidine and metoprolol (3.80%) respectively. Hypo or hypertension (31.65%), decreased drug efficacy (29.11%) and hypo or hyperglycemia (14.14%), were the most commonly reported clinical outcomes of the drug interactions. Cardiovascular drugs (calcium channel blockers and beta blockers; 52%) constitute the major class of drugs involved in interactions. As most of the interactions had a delayed onset, long term follow-up is essential to predict the clinically significant outcomes of these interactions. Hence, drug interactions are commonly seen in the prescriptions of chronic kidney disease patients which can lead to serious adverse events if not detected early. Need for collaboration with a clinical pharmacist and electronic surveillance, which are absent in developing countries like India, is emphatic.

Keywords: Chronic kidney disease; drug interaction; drug related problems; drug-drug interaction; end-stage renal disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda. MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2008.
    1. Clark L, Prescott G, Fluck N, Simpson W, Smith W, Macleod A. Identifying Individuals with CKD: Are we overestimating the number? XLIV Congress of the European Renal Association European Dialysis and Transplant Association (ERA-EDTA), 2007. Nephrol Dial Transplant. 2007;22(Suppl 6):71–90.
    1. Sathvik BS, Mangasuli S, Narahari MG, Gurudev KC, Parthasarathi G. Medication knowledge of hemodialysis patients and influence of clinical pharmacist provided education on their knowledge. Indian J Pharm Sci. 2007;69:232.
    1. Koch-Weser J, Greenblatt DJ. Drug interactions in clinical perspective. Eur J Clin Pharmacol. 1977;11:405–8. - PubMed
    1. Lafleur J, Beth C, Gunning K, Oderda L, Steinvoort C, Oderda GM. Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center. J Manag Care Pharm. 2006;12:677–85. - PMC - PubMed

LinkOut - more resources